Critical Comparison: Cytek Biosciences (NASDAQ:CTKB) and Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience (NASDAQ:HBIOGet Rating) and Cytek Biosciences (NASDAQ:CTKBGet Rating) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Insider and Institutional Ownership

72.8% of Harvard Bioscience shares are held by institutional investors. Comparatively, 36.0% of Cytek Biosciences shares are held by institutional investors. 6.2% of Harvard Bioscience shares are held by company insiders. Comparatively, 15.9% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Harvard Bioscience and Cytek Biosciences, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience 0 0 0 0 N/A
Cytek Biosciences 0 1 2 0 2.67

Cytek Biosciences has a consensus price target of $14.67, indicating a potential upside of 51.05%. Given Cytek Biosciences’ higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than Harvard Bioscience.

Earnings & Valuation

This table compares Harvard Bioscience and Cytek Biosciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $118.90 million 1.28 -$290,000.00 ($0.16) -23.00
Cytek Biosciences $127.95 million 10.19 $3.00 million ($0.02) -485.50

Cytek Biosciences has higher revenue and earnings than Harvard Bioscience. Cytek Biosciences is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.


This table compares Harvard Bioscience and Cytek Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harvard Bioscience -5.38% 9.06% 4.55%
Cytek Biosciences 0.98% 1.78% 1.31%


Cytek Biosciences beats Harvard Bioscience on 8 of the 12 factors compared between the two stocks.

About Harvard Bioscience (Get Rating)

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

About Cytek Biosciences (Get Rating)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with's FREE daily email newsletter.